Transcon CNP Shows Durable Benefits in Achondroplasia Study
At Week 104 of the pivotal ApproaCH trial in children with achondroplasia, once-weekly TransCon CNP (navepegritide) maintained gains in...
Jon Napitupulu
Propanc & Fyonibio Launch Assay for Phase 1b Human Study
Propanc Biopharma has signed a services agreement with Berlin-based FyoniBio to develop and validate an LC-MS pharmacokinetics assay capable...
Aptorum, Diamir Publish microRNA Glioblastoma Biomarker Study
Aptorum Group and DiamiR Biosciences reported peer‑reviewed evidence that plasma microRNA signatures can detect glioblastoma, publishing feasibility findings in...
Polyrizon Launches GMP Manufacturing for U.S. Clinical Trial
Polyrizon has completed GMP manufacturing of clinical trial material for its lead intranasal hydrogel after two prior development batches...
First Volunteer Dosed in Innocare’s New VAV1 Degrader Trial
InnoCare has dosed the first healthy volunteer in China with ICP-538, an oral VAV1-directed molecular glue degrader. It is...
First Patient Dosed in Bioversys’ Phase 2b ALPE TB Trial
In earlier clinical work, the alpibectir–ethionamide combination (AlpE) delivered a 7‑day early bactericidal activity signal comparable to isoniazid and...
BBP-418 Shows Efficacy, Safety in Phase 3 LGMD2I/R9 Study
BridgeBio’s BBP-418 delivered functional and biomarker gains in the Phase 3 FORTIFY interim analysis for LGMD2I/R9: at 12 months,...
Solid Biosciences Duchenne Trial Sees Positive Interim Update
In updated interim data from the Phase 1/2 INSPIRE DUCHENNE study, 40 participants have received SGT-003 to date. Among...
Injectable Buprenorphine Lowers OUD Healthcare Costs, Study
Patients adherent to the monthly extended-release buprenorphine injection for 12 months posted 42% lower adjusted non-MOUD medical costs compared...
Breakthrough Diabetes Study: Positive Results Past One Year
At 14 months post-transplant, a single patient in an investigator-sponsored study maintained detectable fasting and meal-stimulated C-peptide, with mixed-meal...